For chronic weight management, adults may generally qualify for Tirzepatide if they have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition
Ala16Val mutation in Mn-SOD changes the secondary structure of the protein, which may affect the targeting of the protein to mitochondria [63]
Vonlaufen A, Apte MV, Imhof BA et al
However, PYY1-36 primarily stimulates appetite and promotes weight gain, while PYY3-36 is an intestinal-derived satiety hormone believed to have strong anorectic properties, primarily inhibiting appetite and promoting weight loss
The company also implemented a direct-to-consumer campaign, utilizing print, digital, and television ads to inform patients about the drugs benefits